If you have been reading about IGF-1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-20. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Serotonin is a major neurotransmitter in the nervous system and contributes to formation of new neurons (neurogenesis), formation of new connections between neurons (synaptogenesis), remodelling of synapses, and survival and migration of neurons, processes that are necessary for a developing brain and some also necessary for learning in the adult brain. 45% of ASD individuals have been found to have increased blood serotonin levels. Abnormalities in the serotonin transporter have also been found in ASD individuals. It has been hypothesized that increased activity of serotonin in the developing brain may facilitate the onset of ASD, with an association found in six out of eight studies between the use of selective serotonin reuptake inhibitors (SSRIs) by the pregnant mother and the development of ASD in the child exposed to SSRI in the antenatal environment. The study could not definitively conclude SSRIs caused the increased risk for ASD due to the biases found in those studies, and the authors called for more definitive, better conducted studies. Confounding by indication has since then been shown to be likely. However, it is also hypothesized that SSRIs may help reduce symptoms of ASD and even positively affect brain development in some ASD patients.
TabA (P31851), an enzyme related to lysA (diaminopimelate decarboxylase) TabB (P31852), an enzyme related to dapD (THDPA succinyl-CoA succinyltransferase, THDPA-ST) TblA (P31850), an enzyme with no close paralogs (identified as a member of SAMe-dependent methyltransferase superfamily by InterPro) This pathway produces TBL; the enzyme TblF finalize the synthesis by linking TBL to Thr to form tabtoxin.
Sanders supports reducing military spending while pursuing more diplomacy and international cooperation. He opposed funding the Nicaraguan rebels known as the contras in the CIA's covert war against Nicaragua's leftist government. He opposed the US invasion of Iraq and has criticized a number of policies instituted during the war on terror, particularly that of mass surveillance and the USA Patriot Act. He criticized Israel's actions during the 2014 Gaza war and US involvement in the Saudi Arabian-led intervention in Yemen. On November 15, 2015, in response to the Islamic State of Iraq and the Levant (ISIL)'s attacks in Paris, he cautioned against Islamophobia and said, "We gotta be tough, not stupid" in the war against ISIL, adding that the US should continue to welcome Syrian refugees. He criticized the January 2020 drone assassination of Iranian general Qasem Soleimani, calling it a dangerous escalation of tensions that could lead to an expensive war. Sanders supports Palestinian rights and has often criticized Israel, while consistently supporting Israel's right to exist. In 2020, he called the American Israel Public Affairs Committee a platform for bigotry and said he would not attend its conference. He condemned Trump's decision to recognize Jerusalem as Israel's capital, saying, "It would dramatically undermine the prospects for an Israeli–Palestinian peace agreement, and severely, perhaps irreparably, damage the United States' ability to broker that peace." During the Gaza war, he criticized Hamas for the October 7 attacks and Israel for its bombing of Gaza.
== Reactions == Ammonium sulfate decomposes upon heating above 250 °C (482 °F), first forming ammonium bisulfate. Heating at higher temperatures results in decomposition into ammonia, nitrogen, sulfur dioxide, and water. As a salt of a strong acid (H2SO4) and weak base (NH3), its solution is acidic; the pH of 0.1 M solution is 5.5. In aqueous solution the reactions are those of [NH4]+ and SO2−4 ions. For example, addition of barium chloride, precipitates out barium sulfate. The filtrate on evaporation yields ammonium chloride (NH4Cl). Ammonium sulfate forms many double salts (ammonium metal sulfates) when its solution is mixed with equimolar solutions of metal sulfates and the solution is slowly evaporated. With trivalent metal ions, alums such as ferric ammonium sulfate (NH4Fe(SO4)2·12H2O) are formed. Double metal sulfates include ammonium cobaltous sulfate, ferrous diammonium sulfate ((NH4)2SO4·Fe(SO4)·6H2O), ammonium nickel sulfate which are known as Tutton's salts (M2M′(SO4)2(H2O)6) and ammonium ceric sulfate ((NH4)4Ce(SO4)4·2H2O). Anhydrous double sulfates of ammonium also occur in the Langbeinites family. Airborne particles of evaporated ammonium sulfate comprise approximately 30% of fine particulate pollution worldwide. It reacts with additional sulfuric acid to give triammonium hydrogen disulphate, (NH4)3H(SO4)2.
Sources: en.wikipedia.org
=== Metal–organic framework-based nano-adsorbent remediation === Researchers have suggested that metal–organic frameworks (MOFs) and MOF-based nano-adsorbents (MOF-NAs) could be used in the removal of certain CEC, such as pharmaceuticals and personal care products, especially in wastewater treatment. Widespread use of MOF-based nano-adsorbents has yet to be implemented due to complications created by the vast physicochemical properties that CEC contain. The removal of CEC largely depends on the structure and porosity of the MOF-NAs and the physicochemical compatibility of both the CEC and the MOF-NAs. If a CEC is not compatible with the MOF-NA, then particular functional groups can be chemically added to increase compatibility between the two molecules. The addition of functional groups causes the reactions to rely on other chemical processes and mechanisms, such as hydrogen bonding, acid-base reactions, and complex electrostatic forces. MOF-based nano-adsorbent remediation heavily relies on water-qualities, such as pH, in order for the reaction to be executed efficiently. MOF-NA remediation can also be used to efficiently remove other heavy metals and organic compounds in wastewater treatment.
Vasodilators—calcium channel blockers, such as the dihydropyridines nifedipine or amlodipine, preferably slow-release preparations—are often first-line treatment. They have the common side effects of headache, flushing, and ankle edema, but these are not typically of sufficient severity to require cessation of treatment. The limited evidence available shows that calcium-channel blockers are only slightly effective in reducing how often attacks happen, but some studies have found that CCBs may decrease the severity of attacks, pain, and disability associated with Raynaud's phenomenon. People whose disease is secondary to erythromelalgia often cannot use vasodilators for therapy, as they trigger "flares", causing the extremities to become burning red due to too much blood supply. People with severe disease prone to ulceration or large artery thrombotic events may be prescribed aspirin. Sympatholytic agents, such as the alpha-adrenergic blocker prazosin, may provide temporary relief to secondary Raynaud's phenomenon. Angiotensin receptor blockers, such as Losartan, or ACE inhibitors may aid blood flow to the fingers, and there is some evidence that angiotensin receptor blockers (often losartan) reduce frequency and severity of attacks, and possibly better than nifedipine. The prostaglandin iloprost is used to manage critical ischemia and pulmonary hypertension in Raynaud's phenomenon, and the endothelin receptor antagonist bosentan is used to manage severe pulmonary hypertension and prevent finger ulcers in scleroderma.
== Genetics == CTD is caused by pathogenic variants in SLC6A8, located at Xq28. Over 60 variants in SLC6A8 have been reported. SLC6A8 contains 13 exons and spreads across 8.5 kb of genomic DNA (gDNA). The presence of hemizygous variants in males and heterozygous variants in females in SLC6A8 provides evidence that CTD is inherited in an X-linked recessive manner. This usually results in hemizygous males having severe symptoms, while heterozygous female carriers tend to have less severe and more varying symptoms.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.